Cargando…

Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases

AIM: To compare the outcomes of Croatian patients with mantle cell lymphoma (MCL) who started treatment in 2007 and 2008 (historical cohort) and of those who started treatment between 2015 and 2017 (recent cohort). METHODS: The historical cohort consisted of 40 patients who started treatment with ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Bašić-Kinda, Sandra, Mišura Jakobac, Karla, Sinčić-Petričević, Jasminka, Deak, Dajana, Vodanović, Marijo, Jakić-Bubalo, Marinka, Mitrović, Zdravko, Grubešić, Aron, Dreta, Barbara, Županić Krmek, Dubravka, Coha, Božena, Radić-Krišto, Delfa, Aurer, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Croatian Medical Schools 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596472/
https://www.ncbi.nlm.nih.gov/pubmed/34730885
http://dx.doi.org/10.3325/cmj.2021.62.455-63
_version_ 1784600386080866304
author Bašić-Kinda, Sandra
Mišura Jakobac, Karla
Sinčić-Petričević, Jasminka
Deak, Dajana
Vodanović, Marijo
Jakić-Bubalo, Marinka
Mitrović, Zdravko
Grubešić, Aron
Dreta, Barbara
Županić Krmek, Dubravka
Coha, Božena
Radić-Krišto, Delfa
Aurer, Igor
author_facet Bašić-Kinda, Sandra
Mišura Jakobac, Karla
Sinčić-Petričević, Jasminka
Deak, Dajana
Vodanović, Marijo
Jakić-Bubalo, Marinka
Mitrović, Zdravko
Grubešić, Aron
Dreta, Barbara
Županić Krmek, Dubravka
Coha, Božena
Radić-Krišto, Delfa
Aurer, Igor
author_sort Bašić-Kinda, Sandra
collection PubMed
description AIM: To compare the outcomes of Croatian patients with mantle cell lymphoma (MCL) who started treatment in 2007 and 2008 (historical cohort) and of those who started treatment between 2015 and 2017 (recent cohort). METHODS: The historical cohort consisted of 40 patients who started treatment with rituximab in 2007 and 2008. Data on the recent cohort, consisting of 89 patients, were collected retrospectively from the electronic databases of Croatian hospitals with hematology units. Demographic characteristics and data on induction regimens, autologous stem cell transplantation (ASCT), and rituximab maintenance in the first remission, event-free survival (EFS), and overall survival (OS) were available for both cohorts, and data on cell morphology, mantle cell international prognostic index (MIPI), and Ki67 expression only for the recent cohort. RESULTS: The recent cohort had significantly better two-year EFS and OS (EFS 58% vs 40%, P = 0.014; OS 80% vs 56%, P = 0.009), especially in patients below 65. In univariate analysis, induction regimen, ASCT, and maintenance were significant prognostic factors for EFS and the former two for OS. In the multivariate analysis, only ASCT remained significant. Bendamustine + rituximab (BR) induction improved the outcomes of non-transplantable patients over R-CHOP R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, steroid). Blastoid morphology and high MIPI were adverse prognostic factors for EFS and OS. CONCLUSION: In the last decade, the outcome of newly diagnosed MCL patients improved. ASCT in the first remission was the main contributor in transplantable patients and BR in non-transplantable. Regularly updated national guidelines may help in a timely adoption of new treatments, thus improving the results.
format Online
Article
Text
id pubmed-8596472
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Croatian Medical Schools
record_format MEDLINE/PubMed
spelling pubmed-85964722021-11-29 Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases Bašić-Kinda, Sandra Mišura Jakobac, Karla Sinčić-Petričević, Jasminka Deak, Dajana Vodanović, Marijo Jakić-Bubalo, Marinka Mitrović, Zdravko Grubešić, Aron Dreta, Barbara Županić Krmek, Dubravka Coha, Božena Radić-Krišto, Delfa Aurer, Igor Croat Med J Research Article AIM: To compare the outcomes of Croatian patients with mantle cell lymphoma (MCL) who started treatment in 2007 and 2008 (historical cohort) and of those who started treatment between 2015 and 2017 (recent cohort). METHODS: The historical cohort consisted of 40 patients who started treatment with rituximab in 2007 and 2008. Data on the recent cohort, consisting of 89 patients, were collected retrospectively from the electronic databases of Croatian hospitals with hematology units. Demographic characteristics and data on induction regimens, autologous stem cell transplantation (ASCT), and rituximab maintenance in the first remission, event-free survival (EFS), and overall survival (OS) were available for both cohorts, and data on cell morphology, mantle cell international prognostic index (MIPI), and Ki67 expression only for the recent cohort. RESULTS: The recent cohort had significantly better two-year EFS and OS (EFS 58% vs 40%, P = 0.014; OS 80% vs 56%, P = 0.009), especially in patients below 65. In univariate analysis, induction regimen, ASCT, and maintenance were significant prognostic factors for EFS and the former two for OS. In the multivariate analysis, only ASCT remained significant. Bendamustine + rituximab (BR) induction improved the outcomes of non-transplantable patients over R-CHOP R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, steroid). Blastoid morphology and high MIPI were adverse prognostic factors for EFS and OS. CONCLUSION: In the last decade, the outcome of newly diagnosed MCL patients improved. ASCT in the first remission was the main contributor in transplantable patients and BR in non-transplantable. Regularly updated national guidelines may help in a timely adoption of new treatments, thus improving the results. Croatian Medical Schools 2021-10 /pmc/articles/PMC8596472/ /pubmed/34730885 http://dx.doi.org/10.3325/cmj.2021.62.455-63 Text en Copyright © 2021 by the Croatian Medical Journal. All rights reserved. https://creativecommons.org/licenses/by/2.5/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bašić-Kinda, Sandra
Mišura Jakobac, Karla
Sinčić-Petričević, Jasminka
Deak, Dajana
Vodanović, Marijo
Jakić-Bubalo, Marinka
Mitrović, Zdravko
Grubešić, Aron
Dreta, Barbara
Županić Krmek, Dubravka
Coha, Božena
Radić-Krišto, Delfa
Aurer, Igor
Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases
title Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases
title_full Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases
title_fullStr Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases
title_full_unstemmed Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases
title_short Improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the Croatian Cooperative Group for Hematologic Diseases
title_sort improvement in the outcomes of mantle cell lymphoma in the last decade: a real-life non interventional study of the croatian cooperative group for hematologic diseases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596472/
https://www.ncbi.nlm.nih.gov/pubmed/34730885
http://dx.doi.org/10.3325/cmj.2021.62.455-63
work_keys_str_mv AT basickindasandra improvementintheoutcomesofmantlecelllymphomainthelastdecadeareallifenoninterventionalstudyofthecroatiancooperativegroupforhematologicdiseases
AT misurajakobackarla improvementintheoutcomesofmantlecelllymphomainthelastdecadeareallifenoninterventionalstudyofthecroatiancooperativegroupforhematologicdiseases
AT sincicpetricevicjasminka improvementintheoutcomesofmantlecelllymphomainthelastdecadeareallifenoninterventionalstudyofthecroatiancooperativegroupforhematologicdiseases
AT deakdajana improvementintheoutcomesofmantlecelllymphomainthelastdecadeareallifenoninterventionalstudyofthecroatiancooperativegroupforhematologicdiseases
AT vodanovicmarijo improvementintheoutcomesofmantlecelllymphomainthelastdecadeareallifenoninterventionalstudyofthecroatiancooperativegroupforhematologicdiseases
AT jakicbubalomarinka improvementintheoutcomesofmantlecelllymphomainthelastdecadeareallifenoninterventionalstudyofthecroatiancooperativegroupforhematologicdiseases
AT mitroviczdravko improvementintheoutcomesofmantlecelllymphomainthelastdecadeareallifenoninterventionalstudyofthecroatiancooperativegroupforhematologicdiseases
AT grubesicaron improvementintheoutcomesofmantlecelllymphomainthelastdecadeareallifenoninterventionalstudyofthecroatiancooperativegroupforhematologicdiseases
AT dretabarbara improvementintheoutcomesofmantlecelllymphomainthelastdecadeareallifenoninterventionalstudyofthecroatiancooperativegroupforhematologicdiseases
AT zupanickrmekdubravka improvementintheoutcomesofmantlecelllymphomainthelastdecadeareallifenoninterventionalstudyofthecroatiancooperativegroupforhematologicdiseases
AT cohabozena improvementintheoutcomesofmantlecelllymphomainthelastdecadeareallifenoninterventionalstudyofthecroatiancooperativegroupforhematologicdiseases
AT radickristodelfa improvementintheoutcomesofmantlecelllymphomainthelastdecadeareallifenoninterventionalstudyofthecroatiancooperativegroupforhematologicdiseases
AT aurerigor improvementintheoutcomesofmantlecelllymphomainthelastdecadeareallifenoninterventionalstudyofthecroatiancooperativegroupforhematologicdiseases